# ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral

Study · id `cardio:ct-nct06167213` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06167213](<https://clinicaltrials.gov/study/NCT06167213>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06167213

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 125 participants.

## Technical summary

Registry record NCT06167213. Non-randomized; no masking; primary purpose treatment. Start 2027-01 (anticipated); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 125 participants (planned count; ClinicalTrials.gov record NCT06167213, source copy `cardio:ctgov-nct06167213-2025-12-22`, retrieved 2026-10-26)
- Planned start: 2027-01 (anticipated) (ClinicalTrials.gov record NCT06167213, source copy `cardio:ctgov-nct06167213-2025-12-22`, retrieved 2026-10-26)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT06167213, source copy `cardio:ctgov-nct06167213-2025-12-22`, retrieved 2026-10-26)
- Completion: 2038-03 (anticipated) (ClinicalTrials.gov record NCT06167213, source copy `cardio:ctgov-nct06167213-2025-12-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06167213-2025-12-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
- Condition: Mitral Regurgitation
- Condition: Mitral Valve Disease
- Condition: Mitral Stenosis
- Intervention (Device): SAPIEN X4 THV
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry condition terms include this condition: Mitral stenosis (`cardio:mitral-stenosis`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: f1814ac978613d796a669136741949a26cf8da026988b36960df2143548577dd
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
